Update on Treatment Advances for Metastatic Colorectal Cancer: 2009
Einstein-Montefiore Department of Medicine Grand Rounds
Thursday, November 12, 2009
First Floor Lecture Hall, Forchheimer/Einstein
Cherkasky Auditorium, Moses/Montefiore
Edward Chu, MD
Professor of Medicine and Pharmacology
Chief, Section of Medical Oncology
Deputy Director, Yale Cancer Center
Yale University School of Medicine
Dr. Edward Chu is a leading expert in the clinical translational research of colorectal cancer, and his specific area of research interest has been on clinical drug development for colorectal cancer and other GI malignancies. He is the founding Editor-in-Chief of the clinical journal Clinical Colorectal Cancer and is the Chairman of the International Colorectal Congress, which is an annual international meeting focusing on the latest developments in the management and treatment of colorectal cancer. In addition, he is the author of the Physician’ Cancer Chemotherapy Drug Manual, which is now in its eighth edition, and this drug manual includes a comprehensive review of all of the main drugs and drug regimens currently used in clinical practice.
Dr. Chu's research efforts have focused on elucidation of the mechanisms of cytotoxicity and resistance for the antimetabolite class of antineoplastic agents. Specifically, his group has studied the fluoropyrimidine, 5-fluorouracil (5-FU), the most active single agent currently available for the treatment of human colorectal cancer and used in the treatment of a broad range of cancers, including breast and other GI malignancies. His studies are of fundamental importance as they provide new insights as to how tumors become resistant to the effects of cancer chemotherapy. Based on these molecular studies, his clinical research activities are focused on the design and development of novel treatment approaches for human cancers, with a specific focus on colorectal cancer. Finally, his research is also investigating the pharmacoeconomics of various chemotherapy regimens for the treatment of colorectal cancer.
Dr. Chu received his M.D. from Brown University, where he also completed his residency training in Internal Medicine. He then went to the National Cancer Institute in Bethesda, MD for fellowship training in Medical Oncology. Following completion of his fellowship, he remained at the NCI as a Senior Clinical Investigator. In 1996, he was recruited to the Yale Cancer Center where he assumed the positions of Director of the VACT Cancer Center, Associate Director of the VACC of the Yale Cancer Center, and Co-Director of the Developmental Therapeutics Program at the Yale Cancer Center. In July 1, 2004, he was appointed Chief of the Section of Medical Oncology and Deputy Director of Clinical Research of the Yale Cancer Center, and in January 1, 2007, he was appointed as Deputy Director of the Yale Cancer Center.
This grand rounds is hosted by the Division of Oncology.
Albert Einstein College of Medicine designates this educational activity for a maximum of 1 credit towards the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the educational activity.